Protocol Review Committee Members & Procedures

All pharmaceutical, cooperative group, and investigator-initiated protocols either involving patients with cancer or cancer-relevant studies (e.g.: studies about cancer risk factors, prevention, cancer treatment, survivorship or studies that include participants currently or previously diagnosed with cancer or their caregivers) must receive a review by the PRC.  

  • PRC Submissions should be completed via the OnCore system. If you are unfamiliar with OnCore, you may complete this REDCap form. 
  • Protocols will be managed depending on level of reviewreview-flow

* Interventional studies that are funded through a peer-reviewed mechanism or approved by another NCI-CC PRC are expedited 

  • PRC Chair, with the assistance of the PRC coordinator, determines if protocol requires full committee review, if it’s eligible for administrative/expedited review, or if it requires no review (exempt) by the PRC.
  • Single patient INDs are exempt from PRC review.
  • The PRC meets on the second Thursday and fourth Monday of every month, and the deadline for submission is noon two weeks prior to the meeting 
  • The PRC provides the outcome of review by a letter e-mailed to the investigator 
  • Submission to the Institutional Review Board for Health Sciences Research will require a final approval letter from the PRC Chair. 
If you have questions, please contact Saba Mahmood at

PRC Members